doi.org/10.2967/jnumed.120.258889

Original paper

First-in-Humans Study of the SSTR Antagonist ¹⁷⁷Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy

Richard P. Baum

,

,

..., Helmut R. Mäcke

Journal of Nuclear Medicine9.10

Volume: 62, Issue: 11, Pages: 1571 - 1581

Published: Mar 5, 2021

Paper Fields

Paper Details

Title

First-in-Humans Study of the SSTR Antagonist ¹⁷⁷Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy

DOI

doi.org/10.2967/jnumed.120.258889

Published Date

Mar 5, 2021

Journal

Journal of Nuclear Medicine

Volume

62

Issue

11

Pages

1571 - 1581

Notes

History